TY - JOUR T1 - Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1270 LP - 1273 DO - 10.2967/jnumed.120.259226 VL - 62 IS - 9 AU - Mark C. Markowski AU - Pedro Isaacsson Velho AU - Mario A. Eisenberger AU - Martin G. Pomper AU - Kenneth J. Pienta AU - Michael A. Gorin AU - Emmanuel S. Antonarakis AU - Samuel R. Denmeade AU - Steven P. Rowe Y1 - 2021/09/01 UR - http://jnm.snmjournals.org/content/62/9/1270.abstract N2 - Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL–avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression. ER -